INR Monitoring in Cerebral Venous Thrombosis

Target INR Range

The American Society of Hematology provides a strong recommendation for maintaining an INR range of 2.0-3.0 over lower ranges for venous thromboembolism, which includes cerebral venous thrombosis, in patients treated with warfarin 1
The American College of Chest Physicians recommends a therapeutic INR range of 2.0-3.0 with a target of 2.5 for venous thrombotic conditions, including cerebral venous thrombosis 2
Lower INR ranges (1.5-1.9) significantly increase the risk of recurrent thrombosis, with a 3.25-fold increased relative risk and 24 additional thrombotic events per 1000 patients with cerebral venous thrombosis 1

Lower INR ranges may also increase mortality risk (relative risk 2.0) and pulmonary embolism risk (relative risk 5.0) in patients with cerebral venous thrombosis, though these findings did not reach statistical significance 1

After warfarin dose adjustment to achieve therapeutic range, recheck INR within 1 week in patients with cerebral venous thrombosis 3
Once INR reaches therapeutic range (2.0-3.0), monitor weekly for the first month in patients with cerebral venous thrombosis 3

After one month of stable therapeutic INRs, extend monitoring to every 2-4 weeks in patients with cerebral venous thrombosis 3
For consistently stable patients with cerebral venous thrombosis, INR testing can be extended to every 4 weeks, and potentially up to 12 weeks if the patient remains stable 3

Warfarin must be bridged with parenteral anticoagulation (LMWH or unfractionated heparin) for a minimum of 5 days and until INR is ≥2.0 for at least 24 hours, as warfarin initially creates a prothrombotic state in patients with cerebral venous thrombosis 2
Historical INR targets below 2.0 are not validated for safety or efficacy and should be avoided in patients with cerebral venous thrombosis 2

Elderly patients with cerebral venous thrombosis may require lower warfarin doses due to increased sensitivity to anticoagulant effects, but the target INR range remains 2.0-3.0 3
Medication interactions and dietary changes (particularly vitamin K intake) can significantly alter INR values and require patient education in patients with cerebral venous thrombosis 3

Do not use INR targets of 1.5-1.9 or other subtherapeutic ranges—these increase thrombotic risk without reducing bleeding complications in patients with cerebral venous thrombosis 1
Do not discontinue parenteral anticoagulation before achieving therapeutic INR for at least 24 hours in patients with cerebral venous thrombosis 2
Do not extend monitoring intervals too quickly; ensure stability with weekly monitoring for at least one month before extending intervals in patients with cerebral venous thrombosis 3